ASH 2021 - AML

Triplet combination of the anti-CD47 antibody magrolimab + azacitidine and venetoclax was safe and yielded high CR/CRi rates in newly diagnosed AML patients. Read More ›

Addition of the anti-CD70 antibody cusatuzumab to current standard-of-care venetoclax/azacitidine was generally well-tolerated and showed promising antileukemic activity in elderly patients with untreated AML. Read More ›

Triplet combination of IMGN632 (an αCD123 ADC) plus azacitidine and venetoclax was associated with a manageable safety profile and promising antileukemic activity in relapsed/refractory AML patients. Read More ›

Low-intensity regimen of venetoclax plus cladribine/low-dose AraC alternating with azacitidine was well-tolerated and produced high response rates with durable MRD-negative remissions among older/unfit patients with newly diagnosed AML. Read More ›

CD7-targeted CAR-T therapy was associated with a manageable safety profile and produced complete remission in patients with CD7-positive mixed phenotype acute leukemia. Read More ›

Page 2 of 2

Subscribe Today!

To sign up for our free e-Newsletter or print publications, please enter your contact information below.

I'd like to receive:

OPM e-Newsletter
OPM print publication